US medical devices company Endologix, which develops minimally invasive treatments for aortic disorders, signed an agreement with medical devices manufacturer Boston Scientific under which the latter becomes the exclusive distributor for its products in China. The long-term agreement covers distribution rights to Endologix’s EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm Sealing (EVAS) products, and also […]
Continue reading …
Biktarvy China approval : US biopharma company Gilead Sciences said that the China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection. The once-daily single tablet regimen (STR) Biktarvy is a combination of the unboosted integrase strand transfer inhibitor (INSTI) bictegravir and the dual […]
Continue reading …
US finished-dose generic drug company Vitruvias Therapeutics and Chinese pharma company Sinotherapeutics have announced the US launch of a bioequivalent FDA-approved version of antiarrhythmic drug Rythmol SR, known generically as propafenone hydrochloride. Rythmol SR, which is an oral administered drug, is supplied in extended-release capsules of 225, 325 and 425 mg. The antiarrhythmic drug is […]
Continue reading …
Chinese pharma companies Innovent Biologics and Shenzhen Chipscreen Biosciences have agreed to evaluate their respective drugs as combination therapy in advanced colorectal cancer. As per the agreement, Innovent’s Tyvyt (sintilimab injection) and IBI305 – a proposed biosimilar of Roche’s cancer drug bevacizumab will be evaluated in combination with Chipscreen Biosciences’ Chidamide. Tyvyt is a fully […]
Continue reading …Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China
February 11, 2019 No Comment
Samsung Bioepis, a South Korean biopharma company, has signed a licensing agreement with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in China. The agreement covers Samsung Bioepis’ various biosimilar candidates like SB11 and SB12, which reference LUCENTIS (ranibizumab) and SOLIRIS (eculizumab), respectively, and also SB3, a biosimilar candidate referencing HERCEPTIN 3 […]
Continue reading …
InventisBio (Shanghai) has agreed to out-license the rights of its EGFR-T790M tyrosine kinase inhibitor D-0316 in China, Hong Kong and Taiwan to Betta Pharma, in a deal worth more than RMB230 million ($33.44 million). The two Chinese pharma companies have forged a partnership to co-develop the drug in China. D-0316, which was discovered by InventisBio, […]
Continue reading …
US pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth up to $391.5 million for three investigational cancer drugs discovered and developed by the former. The three investigational cancer drugs – pemigatinib, a FGFR1/2/3 inhibitor, itacitinib, a JAK1 inhibitor and parsaclisib, a PI3Kδ inhibitor, are […]
Continue reading …
Japanese biotech company GNI Group will end enrolment of new patients for a phase 2 liver fibrosis trial of its drug candidate F351 in China following the recommendation of an independent data monitoring committee based on the positive efficacy results achieved till date. So far, 175 out of the originally targeted 240 patients have been […]
Continue reading …
Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients having advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The late-stage trial named as FIGHT features advanced gastric cancer or gastroesophageal junction cancer patients who were not subjected to […]
Continue reading …
South Korean biotech company SillaJen and Hong Kong-based Lee’s Pharmaceutical have enrolled the first patient in China for a phase 3 trial called PHOCUS which will evaluate the oncolytic immunotherapy Pexa-Vec for the treatment of advanced liver cancer. The PHOCUS trial will aim to have 600 patients on board across the world who did not […]
Continue reading …
Business News Today
- Western Union joins forces with Du Xiaoman to expand bank account payout in China
- LG Electronics, Luxoft announce webOS automotive joint venture at CES 2020
- Sangomar oil project moves ahead with Senegalese govt approval
- TurkStream gas pipeline project officially launched by Russia and Turkey
- MiraDx to enroll patients for non-tumor based microRNA clinical trial
- ICAP and Charter Realty & Development acquire Baederwood Shoppes
- Superior Plus acquires Western Propane Service in Southern California
- OALP round 4 results : ONGC wins all seven oil and gas blocks
- Johan Sverdrup oil field inaugurated by Norwegian PM Erna Solberg
- KKR acquires Riata Corporate Park in Austin for $258m
